Baltimore-based AsclepiX Therapeutics closed a $35 million Series A financing.

San Diego-based Engrail Therapeutics launched with $32 million in a Series A financing round that was solely funded by Nan Fung Life Sciences (NFLS).

Lassen Therapeutics, based in San Diego, came out of stealth mode with a $31 million Series A financing round.

U.K.-based Bit Bio, a spinout of Cambridge University and previously known as Elpis Biotechnology, secured $41.5 million in a Series A funding round that will be used to support the company’s goal to transition biology into engineering.

Cambridge, Mass.-based QurAlis Corporation increased the company’s financial footing following a $42 million Series A financing round that will be used to support the continued development of therapeutic drugs for ALS and genetically related frontotemporal dementia (FTD).

Nearly two months after inking a licensing deal worth up to $1.5 billion with Swiss pharma giant Roche, Amunix Pharmaceuticals secured $73 million in an oversubscribed Series A financing round that will support the development of the company’s pipeline of novel T cell engagers (XPATs) and cytokines (XPACs).

Leading topics of the 2020 J.P. Morgan Healthcare Conference included a general lack of big deals, defining digital health, and biopharma’s diversity problem.

Bayer and biotechnology company Dewpoint Therapeutics announced an option, research and license agreement worth up to $100 million.

British Columbia-based Chinook Therapeutics burst onto the scene with $65 million in hand and a goal of driving a portfolio of compounds aimed at kidney diseases into the clinic by 2021.

With $28.5 million in financing, Cambridge, Mass.-based Comet Therapeutics is emerging from stealth mode with a focus on developing a portfolio of drug candidates that centers around efforts to re-engineer CoEnzyme-A (CoA).